Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the Bank of America Securities 2023 Health Care Conference. This event is set for May 9, 2023, at 10:00 a.m. (PT), held at the Encore Hotel in Las Vegas, Nevada. Attendees can access a live audio webcast of the presentation on the Teleflex investor website.
Teleflex specializes in medical technologies aimed at enhancing health and quality of life, offering solutions in vascular access, cardiology, anesthesia, and more. Their innovative approaches address critical clinical needs, benefiting patients and healthcare professionals alike.
Teleflex (NYSE: TFX) will host a conference call on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter financial results and operational updates. Participants can pre-register using the provided link to receive dial-in information. The call will be available via audio webcast on the Teleflex website, and a replay will be accessible after 11:00 a.m. ET on the same day. Teleflex is a global leader in medical technologies aimed at enhancing health and quality of life, with a diverse portfolio in areas such as vascular access, anesthesia, and surgical solutions. For further information, stakeholders can visit Teleflex's official website.
Teleflex Incorporated (NYSE: TFX) has announced a supply agreement with W. L. Gore & Associates to integrate GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement into its Titan SGS® Powered Stapling Device for bariatric surgery. This partnership aims to enhance surgical outcomes by combining the advanced technology of the Titan device, specifically designed for sleeve gastrectomy, with Gore's proven staple line reinforcement material. The Titan SGS® offers significant advantages, including reducing stapling time by half and providing a consistent gastric sleeve anatomy. The collaboration highlights both companies' commitment to innovation in the bariatric surgery space.
Teleflex (NYSE: TFX) presented significant findings regarding the UroLift® System for treating benign prostatic hyperplasia (BPH) at the 38th Annual European Association of Urology Congress. Research from over 330 controlled subjects indicates that the UroLift® offers durable results at one and five years, with lower durability linked to undertreatment. Early intervention positively affects quality of life and sexual function. Notably, UroLift® demonstrated a lower complication rate compared to traditional surgeries like TURP. The studies reinforce UroLift® as a leading minimally invasive treatment for BPH, emphasizing its safety and effectiveness.
Teleflex is set to present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 12:00 p.m. (ET). Thomas Powell, the Executive Vice President and Chief Financial Officer, will deliver the presentation. A live audio webcast will be accessible on the Teleflex investor website. Teleflex, traded as TFX on NYSE, specializes in medical technologies aimed at enhancing health and quality of life, offering solutions across various fields including vascular access, anesthesia, and surgical care. For more details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2023. Shareholders of record as of March 3, 2023 will receive this dividend. Teleflex is dedicated to delivering innovative medical technologies aimed at enhancing healthcare quality and outcomes. Their product range spans multiple sectors, including vascular access, interventional cardiology, and anesthesia. This dividend declaration reflects the company's commitment to returning value to its shareholders while supporting ongoing business growth.
Teleflex Incorporated (NYSE: TFX) reported its Q4 2022 financial results, with revenues of $758.0 million, a slight decline of 0.5% year-over-year, but a 3.7% rise on a constant currency basis. GAAP diluted EPS decreased to $1.65 from $2.69 in Q4 2021. For full year 2022, revenues were $2,791.0 million, down 0.7%, with a GAAP diluted EPS of $7.67, compared to $10.23 in 2021. Looking ahead, Teleflex expects revenue growth of 4.25% to 5.75% for 2023, and GAAP EPS guidance of $8.26 to $8.86. The company emphasizes its commitment to durable growth amidst challenges.
Teleflex Incorporated (NYSE: TFX) announced significant advancements in interventional cardiology with the FDA 510(k) clearance of the Triumph™ Catheter and the first clinical use of the GuideLiner® Coast™ Catheter. The Triumph™ Catheter features six wire exit ports designed for better navigation in complex anatomy. Developed with Dr. Bill Nicholson, it aims to improve catheter navigation. The GuideLiner® Coast™ Catheter adds hydrophilic options to the existing portfolio. Both products will be showcased at the CTO Plus Conference on February 23-24 in New York, with full market release expected later in 2023.
Teleflex Incorporated (NYSE: TFX) will have its Chairman, President, and CEO, Liam Kelly, speaking at the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 1:40 p.m. (ET). The conference will take place at the JW Marriott Orlando Grande Lakes, Orlando, FL.
A live audio webcast and accompanying presentation slides will be available on the investor section of Teleflex's website for those unable to attend in person.
Teleflex specializes in innovative medical technologies that improve healthcare quality, offering solutions across various medical fields.
Teleflex Incorporated (NYSE: TFX) will hold a conference call on February 23, 2023, at 8:00 AM ET to discuss its fourth-quarter financial results and provide an operational update. Interested participants can pre-register for the call through a provided link or access it via a live audio webcast on the company’s website. A replay of the call will be available later that day. Teleflex is a leading global provider of medical technologies, focusing on innovative solutions across various healthcare sectors including vascular access, anesthesia, and emergency medicine. For more details, visit their official website.